During the past decade, Retina Associates of Kentucky conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 15 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 11 clinical trials were completed. i.e. 122.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Associates of Kentucky" #1 sponsor was "Jaeb Center for Health Research" with 11 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Kodiak Sciences Inc" with 4 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored and "Clearside Biomedical, Inc." with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Associates of Kentucky" #1 collaborator was "National Eye Institute (NEI)" with 12 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Allergan" with 2 trials as a collaborator and "Kowa Company, Ltd." with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Retina Associates of Kentucky" are "Diabetic Macular Edema" (13 trials), "Diabetic Retinopathy" (5 trials), "Geographic Atrophy" (4 trials), "Age Related Macular Degeneration" (3 trials) and "Macular Degeneration" (3 trials). Many other conditions were trialed in "Retina Associates of Kentucky" in a lesser frequency.

Most popular intervention types in "Retina Associates of Kentucky" are "Drug" (37 trials), "Other" (9 trials), "Procedure" (5 trials), "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (7 trials), "Aflibercept" (6 trials), "KSI-301" (4 trials), "Faricimab" (3 trials) and "Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associates of Kentucky" are 43 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associates of Kentucky". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Retina Associates of Kentucky, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associates of Kentucky, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".